#ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 wer

Stephen V Liu, MD· @StephenVLiu · X·2026-10-24 14:37· 23 小时前评分70

正文 · 原文

#ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 were ctDNA positive at 3w. mPFS 17.8m and OS 31.5m from start of osi - no comparator but encouraging.

187 浏览 · 6 赞 · 2 转发 · 0 回复

会议摘要

2719RO按 Rapid oral 1: NSCLC, metastatic 对上

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)

https://esmocongress.esmo.org

LBA73按 Rapid oral 1: NSCLC, metastatic 对上

PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line

https://esmocongress.esmo.org

来源：Stephen V Liu, MD · x.com